ACG临床指南:特发性药物性肝损伤的诊断与管理
该指南由美国胃肠病学会制定,针对特发性药物性肝损伤(DILI)的診斷与管理提出推荐。DILI需排除其他肝病病因后诊断,MELD评分和合并症负担是死亡重要决定因素,肝细胞性黄疸时死亡率可达10%,进展性黄疸需转诊移植中心。
要点
- DILI为排除性诊断,确诊前需仔细评估其他肝病病因。
- 肝细胞性黄疸的DILI患者死亡率可高达10%。
- 进展性黄疸伴或不伴凝血障碍者应转诊至三级中心评估肝移植。
核心结论
- DILI是排除性诊断,需先排除其他肝病病因。
- MELD评分和合并症负担是疑似DILI患者死亡的重要决定因素。
- 肝细胞性黄疸的DILI死亡率可高达10%。
研究设计与样本
- 美国胃肠病学会(ACG)制定的临床指南。
主要发现
- DILI表现多样,可从无症状肝生化升高到肝细胞性或胆汁淤积性黄疸、肝衰竭或慢性肝炎。
- 西方最常见致病药物类别为抗菌药、草药和膳食补充剂及抗癌治疗(如酪氨酸激酶抑制剂或免疫检查点抑制剂)。
- 肝细胞性黄疸的DILI死亡率可高达10%。
关键数值与推荐
- 进展性黄疸伴或不伴凝血障碍的DILI患者应转诊至三级中心,考虑肝移植。
- 全身性糖皮质激素的作用存在争议,但当肝损伤事件难以区分自身免疫性肝炎与DILI或DILI呈现突出自身免疫性肝炎特征时可使用。
临床怎么用
- 诊断DILI前应仔细评估其他肝病病因。
- 使用MELD评分和合并症负担评估疑似DILI患者死亡风险。
- 进展性黄疸伴或不伴凝血障碍者应及时转诊至三级中心评估肝移植。
- 糖皮质激素仅在难以区分自身免疫性肝炎与DILI或DILI伴突出自身免疫特征时考虑使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Idiosyncratic drug-induced liver injury (DILI) is common in gastroenterology and hepatology practices, and it can have multiple presentations, ranging from asymptomatic elevations in liver biochemistries to hepatocellular or cholestatic jaundice, liver failure, or chronic hepatitis. Antimicrobials, herbal and dietary supplements, and anticancer therapeutics (e.g., tyrosine kinase inhibitors or immune-checkpoint inhibitors) are the most common classes of agents to cause DILI in the Western world. DILI is a diagnosis of exclusion, and thus, careful assessment for other etiologies of liver disease should be undertaken before establishing a diagnosis of DILI. Model for end-stage liver disease score and comorbidity burden are important determinants of mortality in patients presenting with suspected DILI. DILI carries a mortality rate up to 10% when hepatocellular jaundice is present. Patients with DILI who develop progressive jaundice with or without coagulopathy should be referred to a tertiary care center for specialized care, including consideration for potential liver transplantation. The role of systemic corticosteroids is controversial, but they may be administered when a liver injury event cannot be distinguished between autoimmune hepatitis or DILI or when a DILI event presents with prominent autoimmune hepatitis features.
引用
- Chalasani NP, Maddur H, Russo MW, et al. ACG Clinical Guideline: Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury. Am J Gastroenterol. 2021. PMID: 33929376. doi:10.14309/ajg.0000000000001259
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。